2.1. Study Design

This study initially involved 47 patients with chronic kidney disease (CKD), small vessel vasculitis with renal involvement, or previous kidney transplantation. Patients were vaccinated twice, receiving the first dose of Moderna mRNA-1273 in March/April 2021 and the second dose one month later. Written informed consent was obtained in accordance with the Declaration of Helsinki. Data collection and analysis were approved under ECS1236/2021 by the local ethics committee. The vaccination status was queried on the ELGA system (electronic health act), and patients’ characteristics (shown in Table 1) were obtained in the form of routinely collected clinical data.

Patients’ characteristics.

* Data are shown in days as mean (SD) or median [min; max]; ** the number of patients with positive spike antibodies (quantitative antibodies are considered positive from a threshold of ≥7.1 BAU/mL); *** data are shown as median [25% percentile; 75% percentile].